A New Drug Target for Type 2 Diabetes
暂无分享，去创建一个
[1] Nicholette D. Palmer,et al. Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms , 2017, Cell.
[2] Stephen C. J. Parker,et al. The genetic architecture of type 2 diabetes , 2016, Nature.
[3] K. Giacomini,et al. SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.
[4] S. Kahn,et al. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future , 2014, The Lancet.
[5] Tanya M. Teslovich,et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico , 2013, Nature.
[6] A. Halestrap. The SLC16 gene family - structure, role and regulation in health and disease. , 2013, Molecular aspects of medicine.
[7] J. Kere,et al. Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. , 2007, American journal of human genetics.
[8] F. Ashcroft,et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.
[9] A. Hattersley,et al. Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.
[10] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .